Outcomes of Pituitary Radiation for Cushing's Disease

Endocrinol Metab Clin North Am. 2018 Jun;47(2):349-365. doi: 10.1016/j.ecl.2018.01.002. Epub 2018 Apr 9.

Abstract

Achievement of biochemical remission with preservation of normal pituitary function is the goal of treatment for Cushing's disease. For patients with persistent or recurrent Cushing's disease after transsphenoidal resection, radiation therapy may be a safe and effective treatment. Stereotactic radiosurgery is favored over conventional fractionated external beam radiation. Hormonal recurrence rates range from 0% to 36% at 8 years after treatment. Tumor control rates are high. New pituitary hormone deficiency is the most common adverse effect after stereotactic radiosurgery and external beam radiation. The effects of radiation planning optimization and use of adjuvant medication on endocrine remission rates warrant investigation.

Keywords: Cushing’s disease; Endocrine; Radiation therapy; Remission; Stereotactic radiosurgery.

Publication types

  • Review

MeSH terms

  • Humans
  • Pituitary ACTH Hypersecretion / radiotherapy*
  • Pituitary Irradiation / methods*
  • Radiosurgery / methods*